Prolonged remission in Caucasian patients with SLE: prevalence and outcomes

Abstract

AIM: \ud \ud To assess the prevalence of prolonged remission in Caucasian patients affected with systemic lupus erythematosus (SLE) and its relationship with damage accrual.\ud \ud METHODS: \ud \ud Caucasian patients diagnosed with SLE between 1990 and 2009 and quarterly seen from 2009 to 2013 were included in the study. We defined remission as prolonged when lasting ≥5 consecutive years. Three levels of remission were defined using the SLE Disease Activity Index-2000 (SLEDAI-2K): complete remission: no disease activity in corticosteroid-free and immunosuppressant-free patients; clinical remission off corticosteroids: serologically active clinical quiescent (SACQ) disease in corticosteroid-free patients and clinical remission on corticosteroids: SACQ disease in patients taking prednisone 1-5 mg/day. Damage was measured by the SLICC/American College of Rheumatology Damage Index (SDI).\ud \ud RESULTS: \ud \ud 224 patients fulfilled inclusion criteria: 196 (87.5%) were women, mean±SD disease duration 11.2±6.8 years. During the 5-year follow-up, 16 patients (7.1%) achieved prolonged complete remission, 33 (14.7%) prolonged clinical remission off corticosteroids and 35 (15.6%) prolonged clinical remission on corticosteroids. At the multivariate analysis, vasculitis (OR 4.95), glomerulonephritis (OR 2.38) and haematological manifestations (OR 2.19) over the patients' disease course were associated with an unremitted disease. SDI increased more frequently in unremitted (72/140, 51.4%) than in remitted patients (22/84, 26.2%; p=0.001); SDI median increase was higher in unremitted than in remitted patients: 1 (0-3) vs 0 (0-2), respectively (p<0.001). At multivariate analysis, unremitted disease (OR 2.52) and high-dose corticosteroid intake (OR 2.35) were risk factors for damage accrual.\ud \ud CONCLUSIONS: \ud \ud Thirty-seven percent of our Caucasian patients achieved a prolonged remission, which was associated with a better outcome in terms of damage accrual

Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus

“…Using this definition, only 1.7% of their 703 patients achieved sustained remission for more than 5 years. An Italian study reported that 7.1% of their 224 SLE patients achieved sustained remission for 5 years or more, which was defined as a SLEDAI score of 0 and the absence of immunosuppressive therapy except HCQ 10. More recently, a study from UK defined complete SLE remission as clinical inactivity (British Isles Lupus Assessment Group scores of C, D and E only), absence of laboratory evidence of serological activity (normal complement and negative anti-dsDNA) and being off treatment except the antimalarial drugs 12.…”

Calprotectin in rheumatic diseases

“…119 This association supports the idea that the persistence of subclinical inflammation can be responsible for disease progression. 120 CLP seems associated with some clinical manifestations in SLE. Haga et al…”

Remission in SLE: closing in on the target

“…Zen et al 30 present analyses that provide interesting new insights into the questions surrounding remission in SLE. The focus of their studies is on patients in prolonged remission, with analyses of 224 Caucasian patients with SLE diagnosed between 1990 and 2009, and who during a 5-year period between 2009 and 2013 were followed at least three times a year at the registry of patients with SLE at the University of Padua in Italy.…”